“There is substantial epidemiological evidence showing that cannabis increases the risk of psychosis, whereas other research suggests that schizophrenia patients self-medicate with the substance. These conflicting accounts may at least be partially explained by the two phytocannabinoids cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) and their opposing actions on schizophrenia-related symptoms.
…propsychotic actions of THC… antipsychotic actions of CBD.
…animal studies… showing that CBD antagonises the neurobehavioural effects of THC, while others show the opposite, that CBD potentiates the actions of THC.
Various mechanisms are put forth to explain these divergent effects such as CBD antagonism at central CB1 receptors…”
…the present study suggests a beneficial property of a direct cannabinoid receptor agonist… and of CBD…”